The FDA monitors generic drugs after approval using real-time data, adverse event reports, and AI tools to catch safety issues that pre-market studies miss. With 90% of prescriptions being generics, this ongoing surveillance is critical for public health.
Olivia AHOUANGAN | Feb, 20 2026 Read More